Search

Your search keyword '"Rousselot, Philippe"' showing total 555 results

Search Constraints

Start Over You searched for: Author "Rousselot, Philippe" Remove constraint Author: "Rousselot, Philippe" Language english Remove constraint Language: english
555 results on '"Rousselot, Philippe"'

Search Results

1. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

2. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

3. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

4. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

5. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

6. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

8. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

9. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

10. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

11. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

12. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study.

13. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

15. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

16. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.

18. CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial

19. CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials

21. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

25. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs)

26. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

27. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.

28. PPAR[gamma] agonists promote the resolution of myelofibrosis in preclinical models

29. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

30. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

32. Novel precision medicine approaches and treatment strategies in hematological malignancies.

34. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

35. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

36. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

39. CML-425 Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial

40. CLL-431 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study

41. ALL-410 In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph+ ALL

42. Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial

43. 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study

44. In-Depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph+ ALL

46. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study.

47. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

48. Cometary Isotopic Measurements

49. In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

50. Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Catalog

Books, media, physical & digital resources